Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Bought by EntryPoint Capital LLC

EntryPoint Capital LLC lifted its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 101.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 69,526 shares of the company’s stock after buying an additional 34,982 shares during the quarter. EntryPoint Capital LLC owned approximately 0.12% of Olema Pharmaceuticals worth $405,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in OLMA. KLP Kapitalforvaltning AS acquired a new position in Olema Pharmaceuticals during the fourth quarter worth about $30,000. Teacher Retirement System of Texas acquired a new position in shares of Olema Pharmaceuticals during the 4th quarter worth approximately $60,000. Vontobel Holding Ltd. purchased a new stake in Olema Pharmaceuticals in the 4th quarter valued at approximately $62,000. Fox Run Management L.L.C. acquired a new stake in Olema Pharmaceuticals during the 4th quarter valued at $80,000. Finally, SG Americas Securities LLC increased its position in Olema Pharmaceuticals by 33.8% during the fourth quarter. SG Americas Securities LLC now owns 17,475 shares of the company’s stock worth $102,000 after buying an additional 4,419 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Olema Pharmaceuticals Stock Performance

OLMA opened at $4.19 on Wednesday. Olema Pharmaceuticals, Inc. has a 1 year low of $3.94 and a 1 year high of $16.62. The company’s 50 day simple moving average is $5.06 and its 200 day simple moving average is $8.20. The stock has a market capitalization of $286.32 million, a PE ratio of -1.91 and a beta of 2.11.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.12. As a group, sell-side analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on OLMA. Oppenheimer restated an “outperform” rating and issued a $25.00 price objective (down from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th.

Insider Buying and Selling at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of Olema Pharmaceuticals stock in a transaction on Wednesday, January 8th. The shares were purchased at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the transaction, the insider now directly owns 7,800,000 shares in the company, valued at approximately $44,928,000. This represents a 4.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 19.40% of the stock is owned by company insiders.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.